

Bioceres vs Origin Materials
Bioceres Crop Solutions develops agricultural biologicals and transgenic seed technology aimed at improving crop yield under water-stressed conditions in Latin America, while Origin Materials is building a platform to convert sustainable wood residues into bio-based chemicals that can replace petroleum-derived materials. Both companies are early-stage bets on the green transition in their respective supply chains, trading on promise as much as present earnings. Bioceres vs Origin Materials explores two very different approaches to industrial sustainability, one rooted in agtech and the other in bio-manufacturing, with very different risk and revenue trajectories.
Bioceres Crop Solutions develops agricultural biologicals and transgenic seed technology aimed at improving crop yield under water-stressed conditions in Latin America, while Origin Materials is build...
Investment Analysis

Bioceres
BIOX
Pros
- Strong analyst consensus with an average price target implying over 160% upside potential within the next year.
- Improved cash flow management demonstrated by a $40.7 million year-over-year increase in operating cash flow despite revenue declines.
- Successful launch of new biological insecticide and nematicide platform Rinotec™, indicating ongoing innovation in crop protection solutions.
Considerations
- Recent quarters show declining total revenues, with Q3 2025 down 28% year-over-year and crop nutrition segment falling 59%.
- Negative net earnings with a reported loss of $51.8 million trailing twelve months and ongoing quarterly net losses.
- Relatively high debt to equity ratio at 79.2%, which may impact financial flexibility amid operational challenges.

Origin Materials
ORGN
Pros
- Focuses on sustainable materials innovation, targeting growing demand for green chemistry and carbon-negative products.
- Backed by partnerships and strategic investments enhancing scale-up capabilities and commercialisation prospects.
- Positions itself within the expanding bio-based materials sector benefiting from regulatory and consumer trends towards sustainability.
Considerations
- Currently trading at a low market cap around $79 million, reflecting high uncertainty and early development stage risks.
- Negative earnings and price-to-earnings ratio, indicating ongoing losses and unprofitable operations at this stage.
- Limited recent liquidity and scale, which may expose the company to execution risks and funding challenges.
Buy BIOX or ORGN in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.


